Vascular effects of sildenafil in patients with pulmonary fibrosis and pulmonary hypertension: an ex vivo/in vitro study

Milara Javier, Escrivá Juan, Ortiz José Luis, Juan Gustavo, Artigues Enrique, Morcillo Esteban, Cortijo Julio

Source: Eur Respir J 2016; 47:1737-1749
Journal Issue: June
Disease area: Interstitial lung diseases, Pulmonary vascular diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Milara Javier, Escrivá Juan, Ortiz José Luis, Juan Gustavo, Artigues Enrique, Morcillo Esteban, Cortijo Julio. Vascular effects of sildenafil in patients with pulmonary fibrosis and pulmonary hypertension: an ex vivo/in vitro study. Eur Respir J 2016; 47:1737-1749

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Systemic oxygenation affects post-transplantation edema formation and pulmonary artery hypertension in an ex vivo animal model
Source: Annual Congress 2012 - Lung transplantation: studies in candidates and recipients
Year: 2012


Treatment with sildenafil for pulmonary hypertension in pulmonary fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 562s
Year: 2005

Enhanced efficacy of combining imatinib with sildenafil in a rodent model of pulmonary arterial hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010

Acute effect of sildenafil (PDE-5) on cardiopulmonary interactions in patients with pulmonary arterial hypertension (PAH) secondary to pulmonary fibrosis
Source: Annual Congress 2008 - Pulmonary hypertension II
Year: 2008

Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015

Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006


Prevalence of pulmonary arterial hypertension in idiopathic pulmonary fibrosis: a multicenter study
Source: Eur Respir J 2007; 30: Suppl. 51, 119s
Year: 2007

Effects of oral dual ERA therapy on pulmonary function testing and 6MWT in patients with idiopathic pulmonary fibrosis and pulmonary hypertension
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH
Year: 2012

Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study
Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots
Year: 2015


Renal denervation reduces pulmonary vascular remodeling in two experimental pulmonary arterial hypertension models
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015



Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension
Source: Eur Respir J 2010; 36: 808-818
Year: 2010



Caspase inhibition reduces severe pulmonary hypertension in the AdTGF-1β/SU5416 model of angioproliferative pulmonary hypertension and lung fibrosis
Source: Annual Congress 2011 - Experimental pulmonary hypertension
Year: 2011

Clinical characteristics, haemodynamics, and survival in patients with combined pulmonary fibrosis and emphysema and associated pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary vascular medicine
Year: 2008

Bosentan and improved pulmonary endothelial function in pulmonary arterial hypertension
Source: Eur Respir J 2010; 36: 1483-1485
Year: 2010


Dipyridamole as adjuvant therapy in patients with pulmonary arterial hypertension. A pilot study
Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment
Year: 2007



Parenteral treprostinil for significant pulmonary arterial hypertension associated with pulmonary fibrosis: A safety study
Source: Annual Congress 2011 - Treatment of pulmonary hypertension
Year: 2011

Population pharmacokinetics of imatinib in patients with pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013


Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study
Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials
Year: 2017




Regulation of connexins by hypoxia in rat pulmonary vascular cells in an in vitro model of pulmonary hypertension
Source: International Congress 2017 – Experimental PH
Year: 2017


Pulmonary vascular response to exercise in heart-failure patients with pulmonary hypertension: role of a pre-capillary component
Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension
Year: 2017